Tvardi Therapeutics, Inc. (TVRD:NASDAQ) closed at $0.940 on October 23, 2026, down 4.57% on the day. The stock trades 83.5% below its 52-week high of $5.69 and 1.1% above its 52-week low of $0.930. Over the past year, it lost 81.1%. Tvardi Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, TVRD closed higher on 96 days (38%). Its best day was July 8, 2026 (+61.29%) and its worst was June 26, 2026 (-36.44%). The stock moved 10% or more in a single session 12 times.
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Find more stocks like TVRD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.